Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
Phase 3
Completed
- Conditions
- Impetigo
- Registration Number
- NCT00133848
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
Not provided
Exclusion Criteria
- Any signs and symptoms of systemic infection.
- Any serious underlying disease that could be imminently life threatening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response of impetigo at end of therapy visit. Clinical response of success is defined as no further need for antibacterial treatment.
- Secondary Outcome Measures
Name Time Method Clinical response of impetigo at follow up visit. Impetigo lesion area at end of therapy and follow up visits.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of SB-275833 in treating primary impetigo compared to placebo?
How does the efficacy of 1% SB-275833 ointment compare to standard-of-care antibiotics for impetigo in adults and children?
Are there specific biomarkers that correlate with treatment response to SB-275833 in impetigo patients?
What adverse events were observed in the Phase III trial NCT00133848 and how were they managed?
What are the potential advantages of SB-275833 over other topical antibiotics like mupirocin or fusidic acid for impetigo treatment?
Trial Locations
- Locations (1)
GSK Investigational Site
🇵🇪Lima, Peru
GSK Investigational Site🇵🇪Lima, Peru